{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Moderate+Alcohol&page=5", "query": { "intervention": "Moderate Alcohol", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 216, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Moderate+Alcohol&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Moderate+Alcohol&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T00:02:21.078Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03345407", "title": "Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Placebo ELLIPTA", "type": "DRUG" }, { "name": "Nemiralisib ELLIPTA 50 µg", "type": "DRUG" }, { "name": "Nemiralisib ELLIPTA 100 µg", "type": "DRUG" }, { "name": "Nemiralisib ELLIPTA 250 µg", "type": "DRUG" }, { "name": "Nemiralisib ELLIPTA 500 µg", "type": "DRUG" }, { "name": "Nemiralisib ELLIPTA 750 µg", "type": "DRUG" }, { "name": "Albuterol (Salbutamol) MDI or nebules", "type": "DRUG" }, { "name": "Standard of care therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 943, "start_date": "2017-11-28", "completion_date": "2019-01-10", "has_results": true, "last_update_posted_date": "2021-07-14", "last_synced_at": "2026-10-21T00:02:21.078Z", "location_count": 21, "location_summary": "Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Adairsville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03345407" }, { "nct_id": "NCT02210806", "title": "Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "A006 DPI", "type": "DRUG" }, { "name": "Placebo DPI", "type": "OTHER" }, { "name": "Proventil® MDI", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amphastar Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 22, "start_date": "2014-07", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2017-04-19", "last_synced_at": "2026-10-21T00:02:21.078Z", "location_count": 4, "location_summary": "San Jose, California • Medford, Oregon • New Braunfels, Texas + 1 more", "locations": [ { "city": "San Jose", "state": "California" }, { "city": "Medford", "state": "Oregon" }, { "city": "New Braunfels", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02210806" }, { "nct_id": "NCT00092937", "title": "Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Granulomatous Disease", "Chronic" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2, "start_date": "2004-09-23", "completion_date": "2010-04-06", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-21T00:02:21.078Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00092937" }, { "nct_id": "NCT02433834", "title": "Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Glycopyrronium MDI", "type": "DRUG" }, { "name": "Serevent Diskus 50 μg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pearl Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 248, "start_date": "2015-05-27", "completion_date": "2016-03-26", "has_results": true, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-21T00:02:21.078Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02433834" }, { "nct_id": "NCT01437540", "title": "Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium Bromide/Formoterol Fumarate", "type": "DRUG" }, { "name": "Formoterol Fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 590, "start_date": "2011-09-19", "completion_date": "2013-04-30", "has_results": true, "last_update_posted_date": "2017-05-11", "last_synced_at": "2026-10-21T00:02:21.078Z", "location_count": 137, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 110 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01437540" }, { "nct_id": "NCT02233946", "title": "Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prevention Harmful Effects" ], "interventions": [ { "name": "computer-facilitated brief intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "9 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "9 Years to 18 Years" }, "enrollment_count": 871, "start_date": "2015-01", "completion_date": "2018-05-31", "has_results": true, "last_update_posted_date": "2021-03-11", "last_synced_at": "2026-10-21T00:02:21.078Z", "location_count": 5, "location_summary": "Boston, Massachusetts • East Boston, Massachusetts • Lexington, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "East Boston", "state": "Massachusetts" }, { "city": "Lexington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02233946" }, { "nct_id": "NCT01410123", "title": "Integrated Stepped Care for Unhealthy Alcohol Use in HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Liver Diseases, Alcoholic", "Alcoholism", "HIV", "Hepatitis C" ], "interventions": [ { "name": "Integrated Stepped Care (ISC)", "type": "OTHER" }, { "name": "Treatment as Usual", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 319, "start_date": "2013-01", "completion_date": "2018-08-31", "has_results": false, "last_update_posted_date": "2022-12-21", "last_synced_at": "2026-10-21T00:02:21.078Z", "location_count": 5, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • New York, New York + 2 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01410123" }, { "nct_id": "NCT07057310", "title": "Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obesity", "Menopause" ], "interventions": [ { "name": "semaglutide or tirzepatide", "type": "DRUG" }, { "name": "Lifestyle modification intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "46 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "46 Years to 60 Years · Female only" }, "enrollment_count": 30, "start_date": "2025-05-01", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-21T00:02:21.078Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07057310" }, { "nct_id": "NCT05324358", "title": "Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain, Postoperative" ], "interventions": [ { "name": "Ketorolac Tromethamine", "type": "DRUG" }, { "name": "Morphine Sulfate", "type": "DRUG" }, { "name": "Intravenous Placebo for NTM-001", "type": "OTHER" }, { "name": "IV Placebo for Morphine", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Neumentum, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 341, "start_date": "2022-12-14", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-21T00:02:21.078Z", "location_count": 10, "location_summary": "Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Canoga Park", "state": "California" }, { "city": "Pomona", "state": "California" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05324358" }, { "nct_id": "NCT03972488", "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-enteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Lutathera", "type": "DRUG" }, { "name": "30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)", "type": "DRUG" }, { "name": "2.5% Lys-Arg sterile amino acid solution", "type": "DRUG" }, { "name": "High dose 60 mg octreotide long-acting repeatable", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advanced Accelerator Applications", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2020-01-08", "completion_date": "2027-10-29", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-21T00:02:21.078Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03972488" } ] }